Interleukin-18 Binding Protein in the Sera of Patients with Wegener’s Granulomatosis
- D. NovickAffiliated withDepartment of Molecular Genetics, The Weizmann Institute of Science Email author
- , D. ElbirtAffiliated withDepartment of Medicine B, Kaplan Medical Center Rehovot
- , C. A. DinarelloAffiliated withDivision of Infectious Diseases, University of Colorado
- , M. RubinsteinAffiliated withDepartment of Molecular Genetics, The Weizmann Institute of Science
- , Z. M. SthoegerAffiliated withDepartment of Medicine B, Kaplan Medical Center RehovotDepartment of Medicine B Allergy and Clinical Immunology, Kaplan Medical Center Rehovot Email author
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
In the present study, we examined the levels of the pro-inflammatory cytokine IL-18 and its natural inhibitor, the IL-18 binding protein (IL-18BP), in sera of Wegener’s granulomatosis (WG) patients at various stages of the disease.
Patients and Methods
Sera from eight consecutive biopsy-proven systemic WG patients (four men and four women; age at diagnosis 58.4 ± 13.8 years) were obtained longitudinally with a follow-up period of 55.2 ± 30 months. Sera obtained from 50 healthy subjects were used as controls.
Results and Discussion
Serum levels of IL-18, IL-18BP, and free IL-18 obtained during an active phase of the disease (Birmingham Vasculitis Activity Score, BVAS > 10) were more than twofold higher than levels in the same patients during inactive disease stages (BVAS < 5; P < 0.002; P < 0.006, and P < 0.03 for IL-18, IL-18BP, and free IL-18, respectively). During inactive stages, the levels of these markers were comparable to those of healthy controls. The elevated levels of IL-18 and IL-18BP in sera during active stages of disease suggest a possible role in the pathogenesis and course of the WG.
Despite the elevated IL-18BP levels during active disease, free IL-18 remained higher than in the inactive disease stages, suggesting a potential benefit of administration of exogenous IL-18BP as a novel therapeutic approach for active WG.
KeywordsANCA inflammation PR3 cytokines
- Interleukin-18 Binding Protein in the Sera of Patients with Wegener’s Granulomatosis
Journal of Clinical Immunology
Volume 29, Issue 1 , pp 38-45
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Department of Molecular Genetics, The Weizmann Institute of Science, Rehovot, Israel
- 2. Department of Medicine B, Kaplan Medical Center Rehovot, Rehovot, Israel
- 3. Division of Infectious Diseases, University of Colorado, Denver, CO, USA
- 4. Department of Medicine B Allergy and Clinical Immunology, Kaplan Medical Center Rehovot, Rehovot, Israel